榄香烯注射液联合曲妥珠单抗及化疗治疗HER2阳性进展期胃癌的疗效观察  

Therapeutic effect of elemene injection combined with trastuzumab and chemotherapy on patients HER2-positive advanced gastric cancer

作　　者：钟敏 郝成罗[2] ZHONG Min;HAO Cheng-luo(Department of Pharmacy,the Third People’s Hospital of Zigong,Sichuan,Zigong 643020,China;Department of Oncology Hematology,the Third People’s Hospital of Zigong,Sichuan,Zigong 643020,China)

机构地区：[1]自贡市第三人民医院药剂科,四川自贡643020 [2]自贡市第三人民医院肿瘤血液科,四川自贡643020

出　　处：《中国中西医结合消化杂志》2019年第9期662-666,共5页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

摘　　要：[目的]观察榄香烯注射液联合曲妥珠单抗及卡培他滨(XELOX)方案治疗抗人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阳性进展期胃癌患者的疗效及对血清标志物、免疫功能的影响。[方法]选取2015年1月~2018年10月在我院住院治疗的HER2阳性进展期胃癌患者60例为研究对象,按随机数字表法分为观察组及对照组,各30例。对照组予以曲妥珠单抗治疗及XELOX方案化疗,在此基础上,观察组加用榄香烯注射液治疗。比较2组治疗后的近期临床疗效、血清标志物水平及免疫功能。[结果]治疗后,观察组ORR及DCR高于对照组(P<0.05);观察组VEGF、COX-2及MMP-2水平低于对照组(P<0.05);观察组CD4^+细胞比例和CD4^+/CD8^+高于治疗前(P<0.05),观察组CD4^+细胞比例和CD4^+/CD8^+高于对照组(P<0.05)。[结论]榄香烯注射液联合曲妥珠单抗及XELOX方案治疗HER2阳性进展期胃癌能降低患者血清VEGF、COX-2及MMP-2水平,改善免疫功能,提高临床疗效。[Objective]To observe the effect of elemene injection combined with trastuzumab and capecitabine combined with oxaliplatin(XELOX)regimen on advanced gastric cancer patients with positive human epidermal growth factor receptor 2(HER2)as well as on serum markers and immune function.[Methods]60 HER2-positive advanced gastric cancer patients hospitalized in the Third People’s Hospital of Zigong City from January 2015 to October 2018 were selected as the study subjects.Patients were divided into observation group and control group according to random number table method with 30 cases in each group.The control group was treated with trastuzumab and XELOX regimen.The observation group was treated with trastuzumab and XELOX regimen plus elemene injection.The short-term clinical efficacy,serum markers and immune function after the treatment were compared between the two groups.[Results]ORR and DCR in the observation group were higher than those in the control group(P<0.05).The levels of VEGF,COX-2 and MMP-2 in the observation group were lower than those in the control group(P<0.05).The percentage of CD4^+ cells and CD4^+/CD8^+ in the observation group was higher after the treatment(P<0.05)and higher than it was in the control group after the treatment(P<0.05).[Conclusion]Elemene injection combined with trastuzumab and XELOX regimen can reduce the level of serum vascular endothelial growth factor,COX-2 and MMP-2 while improving immune function and clinical efficacy in HER2-positive advanced gastric cancer patients.

关 键 词：榄香烯注射液 曲妥珠单抗 进展期胃癌 免疫 

分 类 号：R735.2[医药卫生—肿瘤]